ALIAS II/III Trial:Albumin Therapy in Ischemic Stroke

ALIAS II/III 试验:白蛋白治疗缺血性中风

基本信息

项目摘要

DESCRIPTION: (Provided by applicant). The objective of this Planning Grant is to provide support to carry out the organizational and grant-writing activities needed to prepare an NIH application for a major Phase II/III Randomized, Multi-center Clinical Trial of Human Serum Albumin (HSAIb) Therapy for Neuroprotection in Acute Ischemic Stroke - the ALIAS Trial. This grant mechanism provides for early peer review of the rationale and design of the proposed trial. Funding is requested to support the following activities: Identification and recruitment of study sites; identification of Steering Committee members, independent medical monitors, and a central pharmacy; finalization of the protocol and case report forms; development of the Manual of Operations and the Data Management Plan; development of innovative alternative statistical-design and -analysis methods; design of a Magnetic Resonance Imaging (MRI) substudy; and preparation of the Phase II/lll ALIAS Trial grant. The multi-functional properties of the albumin molecule render it uniquely suited as a neuroprotective agent, and our pre-clinical investigations have shown consistent high-grade neuroprotection in focal cerebral ischemia. Our NIH-supported Phase I, dose-escalation and safety trial of albumin in acute ischemic stroke (NS 40406), has established the safety of HSAIb at the1 g./kg. i.v. dose (a pre-clinically efficacious dose level) in patients with acute ischemic stroke, and has given us experience in implementing standard assessment measures as a prelude to the Phase II/III ALIAS Trial. The ALIAS Trial consists of a single-arm Phase II futility study; and subsequently, if futility is rejected, a two-arm Phase III efficacy study. Both studies are designed as double-blind, placebo-controlled, randomized, multi-center trials. Two cohorts of subjects will be studied in parallel: A tPA-treated cohort receiving HSAIb within 3 h, and a non-tPA cohort receiving HSAIb within 4.5 h. of stroke onset. At a minimum clinical effect size of 10%, a total of approximately 410 patients is required for the futility trial, and -1,950 for the efficacy trial. The primary outcome measure is the modified Rankin score at 3 months.
描述:(申请人提供)。这项计划拨款的目的是提供支持,以开展所需的组织和赠款撰写活动,以准备NIH申请人血清白蛋白(HSAIb)治疗急性缺血性中风神经保护的重大II/III期随机多中心临床试验-ALIAS试验。这一赠款机制使同行能够及早审查拟议试验的理由和设计。请拨资金支持下列活动:确定和征聘研究地点;确定指导委员会成员、独立医疗监测员和中央药房;最后确定方案和病例报告表;编制《操作手册》和数据管理计划;开发创新的替代统计设计和分析方法;设计磁共振成像分研究;编制第二阶段/第三阶段别名试验赠款。白蛋白分子的多功能特性使其成为一种独特的神经保护剂,我们的临床前研究表明,对局灶性脑缺血具有一致的高级别神经保护作用。我们由美国国立卫生研究院支持的第一阶段,白蛋白在急性缺血性中风中的剂量递增和安全性试验(NS 40406),已经确定HSAIB的安全性为1g/kg。静脉注射。在急性缺血性卒中患者中的临床前有效剂量水平,并使我们在实施标准评估措施作为II/III期ALIAS试验的前奏方面获得了经验。ALIAS试验包括单臂II期无效性研究;随后,如果无效性被拒绝,则双臂III期疗效研究。这两项研究都是双盲、安慰剂对照、随机、多中心试验。将对两组受试者进行平行研究:接受tPA治疗的受试者在卒中开始后3小时内接受HSAIb治疗,而非tPA受试者在卒中开始后4.5小时内接受HSAIb治疗。在最小临床效应规模为10%的情况下,无效试验总共需要大约410名患者,而有效性试验需要-1,950名患者。主要的结果衡量标准是3个月后的改良Rankin评分。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MYRON DAVID GINSBERG其他文献

MYRON DAVID GINSBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MYRON DAVID GINSBERG', 18)}}的其他基金

SHARED CONFOCAL MICROSCOPY FACILITY
共享共焦显微镜设备
  • 批准号:
    6577453
  • 财政年份:
    2003
  • 资助金额:
    $ 20.41万
  • 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
  • 批准号:
    7064212
  • 财政年份:
    2003
  • 资助金额:
    $ 20.41万
  • 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
  • 批准号:
    6669554
  • 财政年份:
    2003
  • 资助金额:
    $ 20.41万
  • 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
  • 批准号:
    6744834
  • 财政年份:
    2003
  • 资助金额:
    $ 20.41万
  • 项目类别:
Azulenyl nitrones: neuroprotectants in stroke and trauma
甘菊硝酮:中风和创伤中的神经保护剂
  • 批准号:
    6877742
  • 财政年份:
    2003
  • 资助金额:
    $ 20.41万
  • 项目类别:
HUMAN ALBUMIN THERAPY OF ACUTE ISCHEMIC STROKE
急性缺血性中风的人白蛋白治疗
  • 批准号:
    6326306
  • 财政年份:
    2001
  • 资助金额:
    $ 20.41万
  • 项目类别:
HUMAN ALBUMIN THERAPY-TREATMENT OF ACUTE ISCHEMIC STROKE
人类白蛋白疗法-治疗急性缺血性中风
  • 批准号:
    6650873
  • 财政年份:
    2001
  • 资助金额:
    $ 20.41万
  • 项目类别:
ACUTE/SUBACUTE METABOLIC & HEMODYNAMIC TRAUMATIC BRAIN INJURY DETERMINANTS
急性/亚急性代谢
  • 批准号:
    6455813
  • 财政年份:
    2001
  • 资助金额:
    $ 20.41万
  • 项目类别:
HUMAN ALBUMIN THERAPY OF ACUTE ISCHEMIC STROKE
急性缺血性中风的人白蛋白治疗
  • 批准号:
    6579862
  • 财政年份:
    2001
  • 资助金额:
    $ 20.41万
  • 项目类别:
HUMAN ALBUMIN THERAPY-TREATMENT OF ACUTE ISCHEMIC STROKE
人白蛋白疗法-治疗急性缺血性中风
  • 批准号:
    6529473
  • 财政年份:
    2001
  • 资助金额:
    $ 20.41万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了